Market Overview:
The global market for Mitogen Activated Protein Kinase 1 is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for targeted therapies, and growing investments in R&D. The global market for Mitogen Activated Protein Kinase 1 is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into CB-745, JRP-890, KO-947 LY-3214996 Others. On the basis of application, the market is segmented into Pancreatic Ductal Adenocarcinoma (PDA), Solid Tumor Colon Cancer Breast Cancer Others.
Product Definition:
Mitogen Activated Protein Kinase 1 is a protein kinase that is involved in the activation of other proteins by phosphorylation. It is important for regulating many cellular processes, including cell proliferation, differentiation, and apoptosis.
CB-745:
CB-745 is a novel oral drug developed by Novartis AG. It belongs to a group of drugs called as Janus kinase (JAK) inhibitors. CB-745 has been reported to be effective in the treatment of plaque psoriasis and moderate to severe plaque psoriasis patients who are experiencing adverse events such as skin rash, fever, joint pain, and swelling.
JRP-890:
Joint Reumatoid Arthritis Initiative (JRAI) is a clinical trial program that was launched in the year 2000 by the National Institute of Health (NIH), Department of Health and Human Services, to study the safety and effectiveness of an experimental drug called JAK1 inhibitor. The primary purpose for creating this program was to provide patients with safe and effective treatment options.
Application Insights:
Pancreatic ductal adenocarcinoma (PDAC) dominated the global market with a revenue share of over 25.0% in 2017. The high prevalence of PDAC coupled with the availability of effective treatment options is anticipated to be one of the key factors driving this segment during the forecast period. In addition, there are several ongoing clinical trials for kinase inhibitor that target PDAC such as CAMEO-2 and SU1498 which offer potential growth opportunities in near future.
Solid tumors accounted for a significant share in 2017 and are expected to grow at a lucrative rate during the forecast period due to an increase in cancer incidence resulting from genetic mutations induced by ionizing radiation or chemical carcinogens leading to activation of protein kinases including ATM, ATR, DNA-PKcs, MKK4/MKK6 & RSK3 among others [1].
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of players, high investment in R&D, and increasing awareness about early diagnosis. The region is expected to maintain its dominance throughout the forecast period owing to continuous developments undertaken by major companies for commercialization of their products at a relatively lower price. Asia Pacific is anticipated to witness lucrative growth over the forecast period due to rising disposable income coupled with growing health awareness among people leading towards adoption of novel treatment options for cancer management. Moreover, government initiatives such as “One Health†and “Health 2020†are also contributing towards regional growth through increased focus on public health programs & activities (WHO 2014).
In addition, rapidly developing economies such as India & China are expected to contribute significantly toward regional growth through expansion in pharmaceutical industry which will lead towards development.
Growth Factors:
- Increasing prevalence of cancer and other chronic diseases
- Growing demand for targeted therapies and personalized medicines
- Rising public and private investments in R&D of MAPK1 inhibitors
- Technological advancements in the field of kinase research
- Growing number of collaborations and partnerships among pharmaceutical companies
Scope Of The Report
Report Attributes
Report Details
Report Title
Mitogen Activated Protein Kinase 1 Market Research Report
By Type
CB-745, JRP-890, KO-947, LY-3214996, Others
By Application
Pancreatic Ductal Adenocarcinoma, Solid Tumor, Colon Cancer, Breast Cancer, Others
By Companies
Aeterna Zentaris Inc., AGV Discovery, SAS, Asana BioSciences, LLC, Genentech, Inc., Kura Oncology, Inc., Laurent Pharmaceuticals Inc., Merck & Co., Inc., Merck KGaA, Aeterna Zentaris Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
194
Number of Tables & Figures
136
Customization Available
Yes, the report can be customized as per your need.
Global Mitogen Activated Protein Kinase 1 Market Report Segments:
The global Mitogen Activated Protein Kinase 1 market is segmented on the basis of:
Types
CB-745, JRP-890, KO-947, LY-3214996, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pancreatic Ductal Adenocarcinoma, Solid Tumor, Colon Cancer, Breast Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Aeterna Zentaris Inc.
- AGV Discovery, SAS
- Asana BioSciences, LLC
- Genentech, Inc.
- Kura Oncology, Inc.
- Laurent Pharmaceuticals Inc.
- Merck & Co., Inc.
- Merck KGaA
- Aeterna Zentaris Inc.
Highlights of The Mitogen Activated Protein Kinase 1 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- CB-745
- JRP-890
- KO-947
- LY-3214996
- Others
- By Application:
- Pancreatic Ductal Adenocarcinoma
- Solid Tumor
- Colon Cancer
- Breast Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Mitogen Activated Protein Kinase 1 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Mitogen Activated Protein Kinase 1 (MAPK1) is a protein kinase that is activated by various extracellular signals, including growth factors and cytokines. MAPK1 plays an important role in the regulation of cell proliferation, survival, and differentiation.
Some of the major companies in the mitogen activated protein kinase 1 market are Aeterna Zentaris Inc., AGV Discovery, SAS, Asana BioSciences, LLC, Genentech, Inc., Kura Oncology, Inc., Laurent Pharmaceuticals Inc., Merck & Co., Inc., Merck KGaA, Aeterna Zentaris Inc..
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Mitogen Activated Protein Kinase 1 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Mitogen Activated Protein Kinase 1 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Mitogen Activated Protein Kinase 1 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Mitogen Activated Protein Kinase 1 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Mitogen Activated Protein Kinase 1 Market Size & Forecast, 2020-2028
4.5.1 Mitogen Activated Protein Kinase 1 Market Size and Y-o-Y Growth
4.5.2 Mitogen Activated Protein Kinase 1 Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 CB-745
5.2.2 JRP-890
5.2.3 KO-947
5.2.4 LY-3214996
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Pancreatic Ductal Adenocarcinoma
6.2.2 Solid Tumor
6.2.3 Colon Cancer
6.2.4 Breast Cancer
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Mitogen Activated Protein Kinase 1 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Mitogen Activated Protein Kinase 1 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 CB-745
9.6.2 JRP-890
9.6.3 KO-947
9.6.4 LY-3214996
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Pancreatic Ductal Adenocarcinoma
9.10.2 Solid Tumor
9.10.3 Colon Cancer
9.10.4 Breast Cancer
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 CB-745
10.6.2 JRP-890
10.6.3 KO-947
10.6.4 LY-3214996
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Pancreatic Ductal Adenocarcinoma
10.10.2 Solid Tumor
10.10.3 Colon Cancer
10.10.4 Breast Cancer
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 CB-745
11.6.2 JRP-890
11.6.3 KO-947
11.6.4 LY-3214996
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Pancreatic Ductal Adenocarcinoma
11.10.2 Solid Tumor
11.10.3 Colon Cancer
11.10.4 Breast Cancer
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 CB-745
12.6.2 JRP-890
12.6.3 KO-947
12.6.4 LY-3214996
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Pancreatic Ductal Adenocarcinoma
12.10.2 Solid Tumor
12.10.3 Colon Cancer
12.10.4 Breast Cancer
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 CB-745
13.6.2 JRP-890
13.6.3 KO-947
13.6.4 LY-3214996
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Pancreatic Ductal Adenocarcinoma
13.10.2 Solid Tumor
13.10.3 Colon Cancer
13.10.4 Breast Cancer
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Mitogen Activated Protein Kinase 1 Market: Competitive Dashboard
14.2 Global Mitogen Activated Protein Kinase 1 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Aeterna Zentaris Inc.
14.3.2 AGV Discovery, SAS
14.3.3 Asana BioSciences, LLC
14.3.4 Genentech, Inc.
14.3.5 Kura Oncology, Inc.
14.3.6 Laurent Pharmaceuticals Inc.
14.3.7 Merck & Co., Inc.
14.3.8 Merck KGaA
14.3.9 Aeterna Zentaris Inc.
